Here's how tesamorelin vs sermorelin and other GHRH peptides compare: GHRH Peptide Comparison Table Property Tesamorelin Sermorelin CJC-1295 (No DAC) CJC-1295 DAC FDA Status FDA Approved (Egrifta) Previously approved, now discontinued Not approved Not approved Amino Acids 44 (modified GHRH) 29 (GHRH 1-29) 29 + modifications 29 + Drug Affinity Complex Half-Life ~26-38 minutes ~10-20 minutes ~30 minutes ~6-8 days Mechanism GHRH receptor agonist GHRH receptor agonist GHRH receptor agonist GHRH receptor agonist (extended) Clinical Trial Data Extensive (Phase 3 completed) Limited (older studies) Limited (Phase 1/2) Limited Primary Research Use Lipodystrophy, NAFLD, body composition GH deficiency research GH axis research Extended GH release research Key Differentiators Tesamorelin's advantages: Only GHRH analog with current FDA approval Extensive Phase 3 clinical trial data Documented efficacy for visceral fat reduction Well-characterized safety profile from prescription use Sermorelin note: Previously FDA-approved (1997) for pediatric growth hormone deficiency but discontinued by manufacturers no longer available as a prescription product in the US
doi: 10.1158/0008-5472.CAN-20-1541 54 PranziniEPardellaEMuccilloLLeoANesiISantiAet al
Specifically, germination increased by 53.28 %, 47.54 % and 45.9 % using melatonin, glutathione or L-cysteine treatments, respectively
What Are The Benefits Of Lipo-Mino
Leyden J., Stephens T., Finkey M., Barkovic S
If you experience a suspected adverse reaction to a cosmetic or topical product, you can report it to the MHRA via the Yellow Card scheme at yellowcard
